<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Biochem</journal-id><journal-title>BMC Biochemistry</journal-title><issn pub-type="epub">1471-2091</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2582802</article-id><article-id pub-id-type="pmid">19007431</article-id><article-id pub-id-type="publisher-id">1471-2091-9-S1-S1</article-id><article-id pub-id-type="doi">10.1186/1471-2091-9-S1-S1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Targeting the UPS as therapy in multiple myeloma</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Chauhan</surname><given-names>Dharminder</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Dharminder_Chauhan@dfci.harvard.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Bianchi</surname><given-names>Giada</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A3" contrib-type="author"><name><surname>Anderson</surname><given-names>Kenneth C</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kenneth_anderson@dfci.harvard.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>21</day><month>10</month><year>2008</year></pub-date><volume>9</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Ubiquitin-Proteasome System in Disease Part 2</named-content><named-content content-type="supplement-editor">John Mayer and Rob Layfield</named-content></supplement><fpage>S1</fpage><lpage>S1</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2091/9/S1/S1"/><permissions><copyright-statement>Copyright &#x000a9; 2008 Chauhan et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Chauhan et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Chauhan
               Dharminder
               
               Dharminder_Chauhan@dfci.harvard.edu
            </dc:author><dc:title>
            Targeting the UPS as therapy in multiple myeloma
         </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Biochemistry 9(Suppl 1): S1-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2091(2008)9:Suppl 1&#x0003c;S1&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2091</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>The coordinated regulation of cellular protein synthesis and degradation is essential for normal cellular functioning. The ubiquitin proteasome system mediates the intracellular protein degradation that is required for normal cellular homeostasis. The 26S proteasome is a multi-enzyme protease that degrades redundant proteins; conversely, inhibition of proteasomal degradation results in intracellular aggregation of unwanted proteins and cell death. This observation led to the development of proteasome inhibitors as therapeutics for use in cancer. The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma. Although bortezomib represents a major advance in the treatment of this disease, it can be associated with toxicity and the development of drug resistance. Importantly, extensive preclinical studies suggest that combination therapies can both circumvent drug resistance and reduce toxicity. In addition, promising novel proteasome inhibitors, which are distinct from bortezomib, and exhibit equipotent anti-multiple myeloma activities, are undergoing clinical evaluation in order to improve patient outcome in multiple myeloma.</p><p>Republished from Current BioData's Targeted Proteins database (TPdb; <ext-link ext-link-type="uri" xlink:href="http://www.targetedproteinsdb.com"/>).</p></abstract></article-meta></front><body><sec><title>Protein pathway involvement in disease</title><sec><title>The ubiquitin proteasome system (UPS)</title><p>Intracellular protein degradation occurs primarily through a multisubunit complex called the proteasome [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Pioneering studies by Ciechanover <italic>et al. </italic>showed that ATP-dependent conjugation of proteins with a polypeptide, ubiquitin (UBIQ), is required for protein degradation [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Subsequent reports demonstrated the role of UBIQ in cellular protein turnover [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>], and it is now well established that ubiquitylation of proteins accounts for their stability, functionality, localization and interactive capabilities [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>UBIQ-mediated proteolysis occurs via the 26S proteasome complex [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B15">15</xref>], which contains 19S units flanking a barrel-shaped 20S proteasome core [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]; the 19S units regulate entry of ubiquitylated proteins into the 20S core chamber [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. Protein breakdown involves sequential enzymatic reactions that culminate in target proteins becoming linked to a chain of UBIQ molecules. In the first reaction, the E1 ubiquitin enzyme activates UBIQ and attaches it to the ubiquitin-conjugating enzyme E2 in an ATP-dependent manner. The E3 ubiquitin ligase then links the UBIQ molecule to the target protein or to a previously attached UBIQ moiety [<xref ref-type="bibr" rid="B20">20</xref>]. Sequential cycles of this process lead to the formation of polyubiquitylated proteins that are eventually degraded by the proteasomes into small peptides, with re-cycling of free UBIQ [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. Importantly, E3 ubiquitin ligases confer specificity in the UBIQ signaling pathway by selectively targeting potential protein substrates for ubiquitylation and subsequent proteasomal degradation [<xref ref-type="bibr" rid="B25">25</xref>]. Three proteasomal activities that regulate proteolysis are chymotrypsin-like (CT-L), trypsin-like (T-L) and caspase-like (C-L), also known as &#x003b2;5, &#x003b2;2 and &#x003b2;1, respectively; all of these reside within the 20S proteasome core [<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B28">28</xref>].</p><p>Proteolysis is a normal cellular process and thus substrates for proteasomes include many cellular proteins that maintain normal cell cycle progression, growth and survival [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. Conversely, pharmacological inhibition of proteasome function hampers the normal elimination of misfolded proteins, thereby causing a build-up of unwanted proteins and eventual cell death [<xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B34">34</xref>]. These laboratory observations have translated into the clinical application of proteasome inhibitors as anticancer therapies. However, since the proteasome regulates normal cellular functions, its inhibition could also trigger toxicity against normal cells [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Importantly, recent studies have shown that proteasome inhibitors are more cytotoxic to proliferating malignant cells than quiescent normal cells, suggesting a favorable therapeutic index [<xref ref-type="bibr" rid="B35">35</xref>-<xref ref-type="bibr" rid="B41">41</xref>].</p></sec><sec><title>Targeting the UPS in multiple myeloma</title><p>As stated in the section <italic>The ubiquitin proteasome system (UPS)</italic>, a broad spectrum of intracellular proteins are substrates for proteasome-mediated degradation. This process involves NF&#x003ba;B, a transcription factor that plays a pivotal role in the inflammatory response and carcinogenesis by controlling genes involved in growth, survival, cell cycle progression, angiogenesis and invasion [<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B44">44</xref>]. Palombella <italic>et al. </italic>showed that the UPS is required for processing the NFKB1 (NF&#x003ba;B1) precursor protein and for activation of NF&#x003ba;B [<xref ref-type="bibr" rid="B45">45</xref>]. Conversely, inhibition of proteasomes by proteasome inhibitor MG132 blocked NF&#x003ba;B activity [<xref ref-type="bibr" rid="B46">46</xref>]. Importantly, our studies showed that adhesion of MM cells to bone marrow stromal cells (BMSCs) triggered transcription and secretion of various cytokines that confer growth, survival and drug resistance in MM cells [<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>]. Other studies further confirmed the role of NF&#x003ba;B as a major growth and survival signaling pathway in MM [<xref ref-type="bibr" rid="B49">49</xref>-<xref ref-type="bibr" rid="B53">53</xref>]. The survival- and growth-promoting role of NF&#x003ba;B in MM, together with the ability of proteasome inhibitors to block NF&#x003ba;B, provided the initial rationale for proteasome inhibitor therapy in MM. Studies by Palombella <italic>et al. </italic>focused on the development of a series of peptide boronic acid inhibitors of the proteasome, in particular bortezomib, and demonstrated their inhibitory activity on NF&#x003ba;B [<xref ref-type="bibr" rid="B46">46</xref>]. The dipeptidyl boronic acid bortezomib is a potent and reversible inhibitor of the CT-L activity of the proteasome [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. Initial NCI screening showed the remarkable antitumor activity of bortezomib against a panel of 60 tumor cell lines [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B54">54</xref>]. Our <italic>in vitro </italic>studies showed that bortezomib downregulates NF&#x003ba;B, blocks constitutive and MM cell adhesion-induced cytokine secretion in BMSCs and induces apoptosis in both MM cell lines and freshly isolated MM cells from patients [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B51">51</xref>]. Moreover, <italic>in vivo </italic>studies using animal models (see <italic>Disease models</italic>, <italic>knockouts</italic>, <italic>assays</italic>) demonstrated a potent anti-MM activity of bortezomib [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B55">55</xref>].</p></sec></sec><sec><title>Disease models, knockouts, assays</title><p>Our <italic>in vitro </italic>findings have also been validated <italic>in vivo </italic>using animal models. These models represent an indispensable bridge between basic research and clinical drug development and have been extensively used in the validation of bortezomib and other novel compounds against MM [<xref ref-type="bibr" rid="B55">55</xref>-<xref ref-type="bibr" rid="B57">57</xref>]. One of the first models to be used was the human plasmacytoma xenograft model, in which triple immunodeficient mice (beige-nude-xid) were injected subcutaneously with MM cells [<xref ref-type="bibr" rid="B55">55</xref>]. This model allows us to simultaneously measure the effect of <italic>in vivo </italic>drug treatment on the growth of human MM cells (assessed by tumor cell size, human idiotypic protein in mouse serum and host survival), as well as the neighboring blood vessels (assessed by microvessel density). Our studies using this model showed that bortezomib inhibits both human MM cell growth and associated angiogenesis <italic>in vivo </italic>[<xref ref-type="bibr" rid="B55">55</xref>].</p><p>Although the human plasmacytoma xenograft model allows for direct assessment of therapy of tumor growth and associated angiogenesis, it does not reflect the bone marrow milieu. For these studies, we have utilized the SCID-hu mouse model developed in our laboratory [<xref ref-type="bibr" rid="B58">58</xref>]. This model examines MM cell growth in the human bone marrow milieu, which includes human BMSCs, extracellular matrix proteins and cytokines, and best reflects the human disease [<xref ref-type="bibr" rid="B58">58</xref>-<xref ref-type="bibr" rid="B60">60</xref>]. In this model, MM cells are injected directly into human fetal bone chips implanted subcutaneously in SCID mice. Tumor growth is assessed by evaluating circulating levels of soluble human IL6R and human monoclonal antibody levels using ELISA [<xref ref-type="bibr" rid="B57">57</xref>]. This model allows us to perform immunohistochemical analysis of excised human bone chips in order to determine MM cell growth <italic>in vivo </italic>using staining with antibodies specific for tumor cells (SYND1 [CD138]). Immunohistochemical analysis of human bone sections from mice treated with various drugs, such as bortezomib, lenalidomide or NPI-0052, can be performed to detect apoptosis (CASP3 [caspase-3] activity, TUNEL staining), growth inhibition (Ki67) and angiogenesis (PECA1 [CD31] and FA8 [Factor VIII staining]). ELISA and human cytokine bead arrays are utilized for analyzing the effect of drugs on human cytokine secretion in mouse serum triggered by human MM-BMSC interactions. This model therefore permits the evaluation of the molecular and cellular changes induced by human MM-human stroma interactions <italic>in vivo</italic>, before and after therapy. We have used this model to validate novel targeted therapies such as CD-138-DM1 antibody [<xref ref-type="bibr" rid="B57">57</xref>] and BAFF inhibitor [<xref ref-type="bibr" rid="B61">61</xref>]. Our ongoing studies are examining the effects of various proteasome inhibitors in this model.</p><p>Validation of the proteasome as a target for antineoplastic therapy has led to the development of assays that not only quantify the bulk of the proteasomes in cells, but also qualitatively assess their function [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Given the differential proteolytic activities of the proteasome and the growing number of available inhibitors, it is essential to establish a relationship between the effectiveness of the drugs and the extent and type of proteasomal blockade. Fluorogenic peptide substrates specific for each proteasomal subunit provide a rapid, sensitive and accurate tool for assessing residual proteasomal activity in crude lysates [<xref ref-type="bibr" rid="B62">62</xref>]. Although extremely useful, these probes require prior cell lysis, thus isolating the proteasome from its functional, regulatory environment [<xref ref-type="bibr" rid="B63">63</xref>]. Moreover, fluorogenic substrates do not differentiate between constitutive and interferon-inducible (immunoproteasome) proteasomal activities [<xref ref-type="bibr" rid="B63">63</xref>]. These limitations have aroused interest in designing cell permeable, specific proteasome probes, such as DansylAhx<sub>3</sub>L<sub>3</sub>VS, capable of monitoring proteasome activity in living cells [<xref ref-type="bibr" rid="B64">64</xref>]. DansylAhx<sub>3</sub>L<sub>3</sub>VS has been proven to be useful for defining the differential activity profiles of the two proteasome inhibitors bortezomib and NPI0052 in MM cell lines [<xref ref-type="bibr" rid="B36">36</xref>]. It was also effective in differentiating between the inhibition of constitutive and inducible proteasomal activity in peripheral blood mononuclear cells from patients undergoing treatment with bortezomib [<xref ref-type="bibr" rid="B65">65</xref>]. These experiments confirm the use of DansylAhx<sub>3</sub>L<sub>3</sub>VS for quantitatively and qualitatively monitoring proteasomal blockade in patients receiving proteasome inhibitor therapy [<xref ref-type="bibr" rid="B65">65</xref>].</p></sec><sec><title>Disease targets and ligands</title><p>Preclinical studies provided the basis for the evaluation of bortezomib as a therapy in MM. A Phase I clinical trial on 27 patients with refractory hematologic malignancies showed anti-MM activity and acceptable toxicity, and in a Phase II trial enrolling 202 relapsed, refractory MM patients, one third of the patients achieved durable responses (with 4% complete responses) and associated clinical benefit. This provided the basis for accelerated FDA approval of bortezomib treatment for relapsed refractory MM [<xref ref-type="bibr" rid="B66">66</xref>,<xref ref-type="bibr" rid="B67">67</xref>]. Thereafter, a randomized Phase III trial on 669 MM patients who had relapsed after at least one prior treatment showed higher responses, as well as prolonged time to progression and survival, after treatment with bortezomib when compared with dexamethasone [<xref ref-type="bibr" rid="B68">68</xref>]. This provided the basis for the extension of FDA approval of bortezomib to include treatment of relapsed MM. Despite the success of bortezomib therapy (43% objective response rates), it has been associated with possible off-target toxicities and the development of drug resistance [<xref ref-type="bibr" rid="B67">67</xref>,<xref ref-type="bibr" rid="B69">69</xref>-<xref ref-type="bibr" rid="B72">72</xref>]. Therefore, extensive laboratory efforts are now focused on delineating the molecular mechanisms mediating bortezomib cytotoxicity and drug resistance, in order to both enhance sensitivity and overcome clinical resistance to bortezomib.</p><sec><title>Mechanistic insights into bortezomib-induced cell death</title><p>Bortezomib-triggered apoptosis in MM cells is associated with inhibition of NF&#x003ba;B; however, whether NF&#x003ba;B blockade is an obligatory event remains unclear. To address this issue, we compared the effects of PS1145, a specific inhibitor of IKKB (IKK-B), with the effects of bortezomib on NF&#x003ba;B and consequent biological response (cell death) in MM cells. Both PS1145 and bortezomib block TNFA (TNF-&#x003b1;)-induced NF&#x003ba;B activation by inhibiting phosphorylation and degradation of IKKB. However, in contrast to bortezomib, PS1145 only partially inhibits MM cell growth [<xref ref-type="bibr" rid="B50">50</xref>]. These findings showed that NF&#x003ba;B inhibition alone is unlikely to account for the overall anti-MM activity of bortezomib. Supportive of these findings, studies to date suggest that bortezomib affects both growth and apoptotic signaling pathways. For example, bortezomib-triggered apoptosis is associated with: activation of heat shock proteins (HSPB1 [Hsp27], Hsp70 and Hsp90) [<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B74">74</xref>]; upregulation of JNK/SAPK [<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B75">75</xref>,<xref ref-type="bibr" rid="B76">76</xref>]; generation of reactive oxygen species [<xref ref-type="bibr" rid="B77">77</xref>]; release of CYC (cytochrome-c)/DBLOH (Smac) from mitochondria into the cytosol and activation of CASP9 (caspase-9) and CASP3 (caspase-3) [<xref ref-type="bibr" rid="B75">75</xref>,<xref ref-type="bibr" rid="B76">76</xref>]; activation of BIM (Bim) and CASP8 (caspase-8) [<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B76">76</xref>]; blockade of DNA repair [<xref ref-type="bibr" rid="B78">78</xref>]; inhibition of MM-BMSC interactions and sequelae including activation of MAPK and PI3K signaling pathways [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B79">79</xref>], and induction of ER stress and an unfolded protein response [<xref ref-type="bibr" rid="B80">80</xref>,<xref ref-type="bibr" rid="B81">81</xref>]. Together, these <italic>in vitro </italic>studies suggest that proteasome inhibition by bortezomib triggers both various apoptotic signaling cascades and blocks growth/survival mechanisms in MM cells [<xref ref-type="bibr" rid="B82">82</xref>].</p></sec></sec><sec><title>New frontiers in drug discovery</title><p>Oncogenomics and proteomic studies in MM cells are identifying and validating key molecules, the pharmacological inhibition of which enhances the antitumor activity of bortezomib and could abrogate drug resistance [<xref ref-type="bibr" rid="B83">83</xref>]. Firstly, bortezomib induces Hsp90 in MM cells, whereas blockade of Hsp90 with 17AAG (Kosan Biosciences, USA) enhances sensitivity and even overcomes resistance to bortezomib [<xref ref-type="bibr" rid="B84">84</xref>]. Ongoing clinical trials show that combination therapy can achieve responses in refractory MM [<xref ref-type="bibr" rid="B85">85</xref>]. Secondly, laboratory studies show that bortezomib induces HSPB1 (Hsp27), and MM cells from patients resistant to bortezomib overexpress HSPB1 [<xref ref-type="bibr" rid="B74">74</xref>,<xref ref-type="bibr" rid="B86">86</xref>]. These findings have already been tested in a clinical trial by combining bortezomib with a p38 MAPK inhibitor, SCIOS469 (Scios USA), which downregulates HSPB1 and overcomes bortezomib resistance [<xref ref-type="bibr" rid="B87">87</xref>,<xref ref-type="bibr" rid="B88">88</xref>]. Thirdly, treatment of MM cell lines and SYND1 (CD138)<sup>+ </sup>MM cells with bortezomib and the novel agents lenalidomide (immunomodulatory agent from Celgene, USA) or CDDO-Imidazolide (a triterpenoid initially synthesized by Honda <italic>et al., </italic>Dartmouth College, USA) induces synergistic anti-MM activity <italic>in vitro </italic>and overcomes resistance to bortezomib by targeting both intrinsic and extrinsic apoptotic signaling. This was evidenced by the disruption of mitochondrial potential and cleavage of CASP9 (caspase-9) and CASP8 (caspase-8) [<xref ref-type="bibr" rid="B89">89</xref>,<xref ref-type="bibr" rid="B90">90</xref>]. These <italic>in vitro </italic>studies provide the basis for clinical protocols combining these agents [<xref ref-type="bibr" rid="B91">91</xref>]. Fourth, bortezomib combined with conventional anti-MM agents such as dexamethasone (Merck USA), doxorubicin (Pharmacia S.p.A, Italy), melphalan (GlaxoSmithKline, UK) or mitoxantrone (Lederle Parenterals, Puerto Rico) induces additive or synergistic antitumor activity in MM cell lines and freshly isolated SYND1<sup>+ </sup>MM cells, as measured by decreased cell viability in colorimetric assays (MTT assay) [<xref ref-type="bibr" rid="B78">78</xref>].</p><p>A recent randomized Phase III trial in 646 patients showed that treatment with pegylated doxorubicin and bortezomib achieved increased overall survival and extent of responses, as well as prolonged time to progression, compared with bortezomib alone. This provided the rationale for FDA approval of this combination for the treatment of relapsed MM [<xref ref-type="bibr" rid="B92">92</xref>,<xref ref-type="bibr" rid="B93">93</xref>]. Finally, our preclinical studies showed that the simultaneous targeting of lysosomal and proteasomal (non-lysosomal mechanism) protein degradation triggers synergistic anti-MM activity [<xref ref-type="bibr" rid="B94">94</xref>,<xref ref-type="bibr" rid="B95">95</xref>]. For example, HDAC6 (HDAC-6) is required for the chaperoning of ubiquitylated proteins for aggresomal degradation. Simultaneous inhibition of proteasomes and aggresomes with bortezomib and tubacin (HDAC6 inhibitor) induces synergistic cytotoxicity in MM cell lines and primary cells from MM patients [<xref ref-type="bibr" rid="B95">95</xref>]. A recent study in pancreatic cancer cells showed that bortezomib triggered the formation of aggresomes (aggregates of ubiquitin-conjugated proteins), which are cytoprotective, whereas their disruption by HDAC6 siRNA induced synergistic apoptosis [<xref ref-type="bibr" rid="B96">96</xref>]. These findings set the stage for the evaluation of combined treatment protocols of bortezomib with HDAC inhibitors in both hematologic malignancies and solid tumors. Our study has already validated the anti-MM activity of HDAC inhibitor LBH589 (Novartis Pharmaceuticals, USA) [<xref ref-type="bibr" rid="B97">97</xref>]; and a Phase I safety study of LBH589, given in combination with bortezomib, is ongoing in MM patients [<xref ref-type="bibr" rid="B98">98</xref>].</p><sec><title>Discovery and validation of novel proteasome inhibitors NPI0052 and PR171 as therapy</title><p>A recent study showed that a novel proteasome inhibitor, NPI0052 (salinosporamide A), is able to overcome bortezomib resistance in MM cells. NPI0052 is a small molecule derived from the fermentation of <italic>Salinospora</italic>, a marine gram-positive actinomycete [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B99">99</xref>,<xref ref-type="bibr" rid="B100">100</xref>]. NPI0052 is a nonpeptide proteasome inhibitor with structural similarity to omuralide. Omuralide is clasto-lactacystin beta-lactone and is the active form of a proteasome inhibitor, lactacystin [<xref ref-type="bibr" rid="B82">82</xref>]. Despite the structural similarity with omuralide, NPI0052 can be distinguished by the presence of a uniquely methylated C3 RING juncture, chlorinated alkyl group at C2 and a cyclohexene ring at C5 [<xref ref-type="bibr" rid="B82">82</xref>,<xref ref-type="bibr" rid="B99">99</xref>-<xref ref-type="bibr" rid="B101">101</xref>]. Initial screening of NPI0052 against the NCI panel of 60 tumor cell lines showed an IC<sub>50 </sub>of &#x0003c; 10 nM in all cases. Importantly, NPI0052 similarly triggered apoptosis in purified tumor cells from several MM patients relapsing after prior therapies including bortezomib and thalidomide [<xref ref-type="bibr" rid="B36">36</xref>]. <italic>In vivo </italic>efficacy of NPI0052 was shown using a human plasmacytoma xenograft mouse model. Specifically, NPI0052 inhibited MM tumor growth and prolonged survival of these mice at concentrations that were well tolerated, without weight loss or neurological changes [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B55">55</xref>]. Another study showed that NPI0052 is a more effective inducer of apoptosis than bortezomib in lymphocytic leukemic cells [<xref ref-type="bibr" rid="B102">102</xref>].</p><p>Examination of signal transduction pathways in MM cells showed that: NPI0052 is a more potent inhibitor of NF&#x003ba;B and related cytokine transcription and secretion than bortezomib; NPI0052-induced MM cell death is predominantly mediated by CASP8 and bortezomib-induced apoptosis requires both CASP8 and CASP9 activation [<xref ref-type="bibr" rid="B36">36</xref>]. Moreover, NPI0052 and bortezomib differentially affect 20S proteasomal activities; NPI0052 inhibits all three proteasomal activities, i.e. CT-L, T-L and C-L, whereas bortezomib blocks CT-L and C-L but not T-L activities [<xref ref-type="bibr" rid="B36">36</xref>]. A recent study showed that simultaneous inhibition of multiple proteasome activities is a prerequisite for significant (i.e. &#x0003e; 50%) proteolysis [<xref ref-type="bibr" rid="B62">62</xref>]. Another study showed that 50% inhibition of CFTR degradation in reticulocyte extracts requires concurrent blockade of CT-L and C-L proteasome activities [<xref ref-type="bibr" rid="B103">103</xref>]. Whether blocking all three activities is therapeutically advantageous will be evaluated in clinical trials of NPI0052. Nonetheless, the mechanistic differences between NPI0052 and bortezomib, i.e. their differential effect on proteasome activities and their dependence on specific apoptotic signal transduction pathways, provides a rationale for combination proteasome inhibitor regimens to enhance MM cytotoxicity. Indeed, the combination of NPI0052 with bortezomib induces synergistic anti-MM activity, without significantly affecting the viability of normal lymphocytes [<xref ref-type="bibr" rid="B36">36</xref>]. Enhanced cytotoxicity of the combination regimen could be due to higher levels of proteasome inhibition with the two drug regimens and/or activation of differential apoptotic signaling pathways. Nevertheless, these preliminary studies set the stage for clinical trials of combined proteasome inhibitors to improve patient outcome in MM.</p><p>Finally, PR171 or carfilzomib (Proteolix, USA) is another novel proteasome inhibitor. PR171 [<xref ref-type="bibr" rid="B104">104</xref>-<xref ref-type="bibr" rid="B106">106</xref>] is an irreversible proteasome inhibitor, predominantly targeting CT-L activity and triggering potent antitumor activity [<xref ref-type="bibr" rid="B104">104</xref>,<xref ref-type="bibr" rid="B105">105</xref>]. A Phase I trial demonstrated tolerability and responses [<xref ref-type="bibr" rid="B107">107</xref>] and Phase II trails are ongoing in relapsed/refractory MM [<xref ref-type="bibr" rid="B108">108</xref>]. Laboratory studies are currently examining whether PR171 can be combined with bortezomib to induce synergistic cytotoxicity in MM cells.</p></sec></sec><sec><title>Conclusion</title><p>Delineation of the molecular and cellular mechanisms of bortezomib-induced apoptosis [<xref ref-type="bibr" rid="B79">79</xref>,<xref ref-type="bibr" rid="B109">109</xref>] has provided the rationale for combining bortezomib with conventional (dexamethasone, doxorubicin, melphalan) and novel (lenalidomide, HSP inhibitors, HDAC inhibitors) agents in order to reduce toxicity, enhance cytotoxicity and overcome drug resistance. Although bortezomib and NPI0052 belong to the same class of drugs, they are distinct in their mode of action and can be rationally combined as therapy [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B102">102</xref>,<xref ref-type="bibr" rid="B110">110</xref>]. The synergy observed in preliminary studies suggests an increased therapeutic index of combined therapy. However, more definitive evidence of enhanced efficacy of this combination regimen awaits careful clinical trials.</p></sec><sec><title>List of abbreviations used</title><p>BMSC: bone marrow stromal cell; C-L: caspase-like; CT-L: chymotrypsin-like; MM: multiple myeloma; T-L: trypsin-like; UPS: ubiquitin proteasome system.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Publication history</title><p>Republished from Current BioData's Targeted Proteins database (TPdb; <ext-link ext-link-type="uri" xlink:href="http://www.targetedproteinsdb.com"/>).</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This research study was supported by: NIH grants CA 50947, CA 78373, CA100707-01, a Doris Duke Distinguished Clinical Research Scientist Award (KCA), and The Cure for Myeloma Fund.</p><p>This article has been published as part of <italic>BMC Biochemistry </italic>Volume 9 Supplement 1, 2008: Ubiquitin-Proteasome System in Disease Part 2. The full contents of the supplement are available online at <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2091/9?issue=S1"/>.</p><p>Additional TPdb reviews on the ubiquitin-proteasome system are also available in <italic>BMC Biochemistry </italic>&#x02013; see Volume 8 Suppl 1 <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2091/8?issue=S1"/>.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>K</given-names></name><name><surname>Gramm</surname><given-names>C</given-names></name><name><surname>Rothstein</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>K</given-names></name><name><surname>Stein</surname><given-names>R</given-names></name><name><surname>Dick</surname><given-names>L</given-names></name><name><surname>Hwang</surname><given-names>D</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name></person-group><article-title>Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules</article-title><source>Cell</source><year>1994</year><volume>78</volume><fpage>761</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">8087844</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(94)90462-6</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Protein degradation and protection against misfolded or damaged proteins</article-title><source>Nature</source><year>2003</year><volume>426</volume><fpage>895</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">14685250</pub-id><pub-id pub-id-type="doi">10.1038/nature02263</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name></person-group><article-title>The proteasome: a suitable antineoplastic target</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>349</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">15122206</pub-id><pub-id pub-id-type="doi">10.1038/nrc1361</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Elias</surname><given-names>S</given-names></name><name><surname>Heller</surname><given-names>H</given-names></name><name><surname>Ferber</surname><given-names>S</given-names></name><name><surname>Hershko</surname><given-names>A</given-names></name></person-group><article-title>Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes</article-title><source>J Biol Chem</source><year>1980</year><volume>255</volume><fpage>7525</fpage><lpage>7528</lpage><pub-id pub-id-type="pmid">6249802</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Heller</surname><given-names>H</given-names></name><name><surname>Elias</surname><given-names>S</given-names></name><name><surname>Haas</surname><given-names>A</given-names></name><name><surname>Hershko</surname><given-names>A</given-names></name></person-group><article-title>ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation</article-title><source>Proc Natl Acad Sci USA</source><year>1980</year><volume>77</volume><fpage>1365</fpage><lpage>1368</lpage><pub-id pub-id-type="pmid">6769112</pub-id><pub-id pub-id-type="doi">10.1073/pnas.77.3.1365</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Rose</surname><given-names>I</given-names></name></person-group><article-title>Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP</article-title><source>Proc Natl Acad Sci USA</source><year>1979</year><volume>76</volume><fpage>3107</fpage><lpage>3110</lpage><pub-id pub-id-type="pmid">290989</pub-id><pub-id pub-id-type="doi">10.1073/pnas.76.7.3107</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Heller</surname><given-names>H</given-names></name><name><surname>Haas</surname><given-names>A</given-names></name><name><surname>Rose</surname><given-names>I</given-names></name></person-group><article-title>Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis</article-title><source>Proc Natl Acad Sci USA</source><year>1980</year><volume>77</volume><fpage>1783</fpage><lpage>1786</lpage><pub-id pub-id-type="pmid">6990414</pub-id><pub-id pub-id-type="doi">10.1073/pnas.77.4.1783</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Finley</surname><given-names>D</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group><article-title>Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85</article-title><source>Cell</source><year>1984</year><volume>37</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">6327060</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(84)90300-3</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Eytan</surname><given-names>E</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Haas</surname><given-names>A</given-names></name></person-group><article-title>Immunochemical analysis of the turnover of ubiquitin-protein conjugates in intact cells. Relationship to the breakdown of abnormal proteins</article-title><source>J Biol Chem</source><year>1982</year><volume>257</volume><fpage>13964</fpage><lpage>13970</lpage><pub-id pub-id-type="pmid">6292216</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name><surname>Riezman</surname><given-names>H</given-names></name></person-group><article-title>Proteasome-independent functions of ubiquitin in endocytosis and signaling</article-title><source>Science</source><year>2007</year><volume>315</volume><fpage>201</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">17218518</pub-id><pub-id pub-id-type="doi">10.1126/science.1127085</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilk</surname><given-names>S</given-names></name><name><surname>Orlowski</surname><given-names>M</given-names></name></person-group><article-title>Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex</article-title><source>J Neurochem</source><year>1983</year><volume>40</volume><fpage>842</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">6338156</pub-id><pub-id pub-id-type="doi">10.1111/j.1471-4159.1983.tb08056.x</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eytan</surname><given-names>E</given-names></name><name><surname>Ganoth</surname><given-names>D</given-names></name><name><surname>Armon</surname><given-names>T</given-names></name><name><surname>Hershko</surname><given-names>A</given-names></name></person-group><article-title>ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin</article-title><source>Proc Natl Acad Sci USA</source><year>1989</year><volume>86</volume><fpage>7751</fpage><lpage>7755</lpage><pub-id pub-id-type="pmid">2554287</pub-id><pub-id pub-id-type="doi">10.1073/pnas.86.20.7751</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hough</surname><given-names>R</given-names></name><name><surname>Pratt</surname><given-names>G</given-names></name><name><surname>Rechsteiner</surname><given-names>M</given-names></name></person-group><article-title>Purification of two high molecular weight proteases from rabbit reticulocyte lysate</article-title><source>J Biol Chem</source><year>1987</year><volume>262</volume><fpage>8303</fpage><lpage>8313</lpage><pub-id pub-id-type="pmid">3298229</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waxman</surname><given-names>L</given-names></name><name><surname>Fagan</surname><given-names>JM</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Demonstration of two distinct high molecular weight proteases in rabbit reticulocytes, one of which degrades ubiquitin conjugates</article-title><source>J Biol Chem</source><year>1987</year><volume>262</volume><fpage>2451</fpage><lpage>2457</lpage><pub-id pub-id-type="pmid">3029081</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Driscoll</surname><given-names>J</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins</article-title><source>J Biol Chem</source><year>1990</year><volume>265</volume><fpage>4789</fpage><lpage>4792</lpage><pub-id pub-id-type="pmid">2180950</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ganoth</surname><given-names>D</given-names></name><name><surname>Leshinsky</surname><given-names>E</given-names></name><name><surname>Eytan</surname><given-names>E</given-names></name><name><surname>Hershko</surname><given-names>A</given-names></name></person-group><article-title>A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation</article-title><source>J Biol Chem</source><year>1988</year><volume>263</volume><fpage>12412</fpage><lpage>12419</lpage><pub-id pub-id-type="pmid">2842333</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arrigo</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name><name><surname>Welch</surname><given-names>W</given-names></name></person-group><article-title>Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome)</article-title><source>Nature</source><year>1988</year><volume>331</volume><fpage>192</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">3277060</pub-id><pub-id pub-id-type="doi">10.1038/331192a0</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Cejka</surname><given-names>Z</given-names></name><name><surname>Harris</surname><given-names>JR</given-names></name><name><surname>Kleinschmidt</surname><given-names>JA</given-names></name><name><surname>Baumeister</surname><given-names>W</given-names></name></person-group><article-title>Structural features of the 26 S proteasome complex</article-title><source>J Mol Biol</source><year>1993</year><volume>234</volume><fpage>932</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">8263938</pub-id><pub-id pub-id-type="doi">10.1006/jmbi.1993.1646</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>C</given-names></name><name><surname>Slaughter</surname><given-names>C</given-names></name><name><surname>DeMartino</surname><given-names>G</given-names></name></person-group><article-title>PA28 activator protein forms regulatory caps on proteasome stacked rings</article-title><source>J Mol Biol</source><year>1994</year><volume>236</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">8107126</pub-id><pub-id pub-id-type="doi">10.1006/jmbi.1994.1113</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Heller</surname><given-names>H</given-names></name><name><surname>Elias</surname><given-names>S</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name></person-group><article-title>Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown</article-title><source>J Biol Chem</source><year>1983</year><volume>258</volume><fpage>8206</fpage><lpage>8214</lpage><pub-id pub-id-type="pmid">6305978</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>K</given-names></name><name><surname>Urban</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>A</given-names></name></person-group><article-title>Ubiquitin is the ATP-dependent proteolysis factor I of rabbit reticulocytes</article-title><source>J Biol Chem</source><year>1980</year><volume>255</volume><fpage>7529</fpage><lpage>7532</lpage><pub-id pub-id-type="pmid">6249803</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hough</surname><given-names>R</given-names></name><name><surname>Pratt</surname><given-names>G</given-names></name><name><surname>Rechsteiner</surname><given-names>M</given-names></name></person-group><article-title>Ubiquitin-lysozyme conjugates. Identification and characterization of an ATP-dependent protease from rabbit reticulocyte lysates</article-title><source>J Biol Chem</source><year>1986</year><volume>261</volume><fpage>2400</fpage><lpage>2408</lpage><pub-id pub-id-type="pmid">3003114</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Amerik</surname><given-names>A</given-names></name><name><surname>Hochstrasser</surname><given-names>M</given-names></name></person-group><article-title>The Doa4 deubiquitinating enzyme is required for ubiquitin homeostasis in yeast</article-title><source>Mol Biol Cell</source><year>1999</year><volume>10</volume><fpage>2583</fpage><lpage>2594</lpage><pub-id pub-id-type="pmid">10436014</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pickart</surname><given-names>C</given-names></name></person-group><article-title>Targeting of substrates to the 26S proteasome</article-title><source>Faseb J</source><year>1997</year><volume>11</volume><fpage>1055</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">9367341</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hershko</surname><given-names>A</given-names></name></person-group><article-title>The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle</article-title><source>Cell Death Differ</source><year>2005</year><volume>12</volume><fpage>1191</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">16094395</pub-id><pub-id pub-id-type="doi">10.1038/sj.cdd.4401702</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arendt</surname><given-names>C</given-names></name><name><surname>Hochstrasser</surname><given-names>M</given-names></name></person-group><article-title>Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>7156</fpage><lpage>7161</lpage><pub-id pub-id-type="pmid">9207060</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.14.7156</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heinemeyer</surname><given-names>W</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Krimmer</surname><given-names>T</given-names></name><name><surname>Stachon</surname><given-names>U</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name></person-group><article-title>The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>25200</fpage><lpage>25209</lpage><pub-id pub-id-type="pmid">9312134</pub-id><pub-id pub-id-type="doi">10.1074/jbc.272.40.25200</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kisselev</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name></person-group><article-title>Proteasome inhibitors: from research tools to drug candidates</article-title><source>Chem Biol</source><year>2001</year><volume>8</volume><fpage>739</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">11514224</pub-id><pub-id pub-id-type="doi">10.1016/S1074-5521(01)00056-4</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glotzer</surname><given-names>M</given-names></name><name><surname>Murray</surname><given-names>A</given-names></name><name><surname>Kirschner</surname><given-names>M</given-names></name></person-group><article-title>Cyclin is degraded by the ubiquitin pathway</article-title><source>Nature</source><year>1991</year><volume>349</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">1846030</pub-id><pub-id pub-id-type="doi">10.1038/349132a0</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname><given-names>M</given-names></name><name><surname>Tam</surname><given-names>S</given-names></name><name><surname>Theodoras</surname><given-names>A</given-names></name><name><surname>Beer-Romero</surname><given-names>P</given-names></name><name><surname>Del</surname><given-names>SG</given-names></name><name><surname>Chau</surname><given-names>V</given-names></name><name><surname>Yew</surname><given-names>P</given-names></name><name><surname>Draetta</surname><given-names>G</given-names></name><name><surname>Rolfe</surname><given-names>M</given-names></name></person-group><article-title>Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27</article-title><source>Science</source><year>1995</year><volume>269</volume><fpage>682</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">7624798</pub-id><pub-id pub-id-type="doi">10.1126/science.7624798</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Tenev</surname><given-names>T</given-names></name><name><surname>Martins</surname><given-names>L</given-names></name><name><surname>Downward</surname><given-names>J</given-names></name><name><surname>Lemoine</surname><given-names>N</given-names></name></person-group><article-title>The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner</article-title><source>J Cell Sci</source><year>2000</year><volume>113</volume><fpage>4363</fpage><lpage>4371</lpage><pub-id pub-id-type="pmid">11069780</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finley</surname><given-names>D</given-names></name><name><surname>Sadis</surname><given-names>S</given-names></name><name><surname>Monia</surname><given-names>B</given-names></name><name><surname>Boucher</surname><given-names>P</given-names></name><name><surname>Ecker</surname><given-names>D</given-names></name><name><surname>Crooke</surname><given-names>S</given-names></name><name><surname>Chau</surname><given-names>V</given-names></name></person-group><article-title>Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant</article-title><source>Mol Cell Biol</source><year>1994</year><volume>14</volume><fpage>5501</fpage><lpage>5509</lpage><pub-id pub-id-type="pmid">8035826</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>Sausville</surname><given-names>EA</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Destree</surname><given-names>A</given-names></name><name><surname>Lazarus</surname><given-names>DD</given-names></name><name><surname>Maas</surname><given-names>J</given-names></name><name><surname>Pien</surname><given-names>CS</given-names></name><name><surname>Prakash</surname><given-names>S</given-names></name><name><surname>Elliott</surname><given-names>PJ</given-names></name></person-group><article-title>Proteasome inhibitors: a novel class of potent and effective antitumor agents</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>2615</fpage><lpage>2622</lpage><pub-id pub-id-type="pmid">10363983</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dantuma</surname><given-names>N</given-names></name><name><surname>Lindsten</surname><given-names>K</given-names></name><name><surname>Glas</surname><given-names>R</given-names></name><name><surname>Jellne</surname><given-names>M</given-names></name><name><surname>Masucci</surname><given-names>M</given-names></name></person-group><article-title>Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells</article-title><source>Nat Biotechnol</source><year>2000</year><volume>18</volume><fpage>538</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">10802622</pub-id><pub-id pub-id-type="doi">10.1038/75406</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Palombella</surname><given-names>V</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3071</fpage><lpage>3076</lpage><pub-id pub-id-type="pmid">11306489</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Catley</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Velankar</surname><given-names>M</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Yasui</surname><given-names>H</given-names></name><name><surname>Letai</surname><given-names>A</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Berkers</surname><given-names>C</given-names></name><name><surname>Nicholson</surname><given-names>B</given-names></name><name><surname>Chao</surname><given-names>TH</given-names></name><name><surname>Neuteboom</surname><given-names>ST</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Palladino</surname><given-names>MA</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib</article-title><source>Cancer Cell</source><year>2005</year><volume>8</volume><fpage>407</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">16286248</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2005.10.013</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masdehors</surname><given-names>P</given-names></name><name><surname>Omura</surname><given-names>S</given-names></name><name><surname>Merle-Beral</surname><given-names>H</given-names></name><name><surname>Mentz</surname><given-names>F</given-names></name><name><surname>Cosset</surname><given-names>JM</given-names></name><name><surname>Dumont</surname><given-names>J</given-names></name><name><surname>Magdelenat</surname><given-names>H</given-names></name><name><surname>Delic</surname><given-names>J</given-names></name></person-group><article-title>Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin</article-title><source>Br J Haematol</source><year>1999</year><volume>105</volume><fpage>752</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">10354141</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2141.1999.01388.x</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>HC</given-names></name><name><surname>Risau</surname><given-names>W</given-names></name><name><surname>Konerding</surname><given-names>MA</given-names></name></person-group><article-title>Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells</article-title><source>Faseb J</source><year>2000</year><volume>14</volume><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10627281</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>Y</given-names></name><name><surname>Takata</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>I</given-names></name><name><surname>Kaneda</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Takekoshi</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Miyauchi</surname><given-names>M</given-names></name><name><surname>Nikai</surname><given-names>H</given-names></name></person-group><article-title>p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>916</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">10741716</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogner</surname><given-names>C</given-names></name><name><surname>Schneller</surname><given-names>F</given-names></name><name><surname>Hipp</surname><given-names>S</given-names></name><name><surname>Ringshausen</surname><given-names>I</given-names></name><name><surname>Peschel</surname><given-names>C</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name></person-group><article-title>Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways</article-title><source>Exp Hematol</source><year>2003</year><volume>31</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">12644019</pub-id><pub-id pub-id-type="doi">10.1016/S0301-472X(02)01076-7</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name></person-group><article-title>Development of the proteasome inhibitor Velcade (Bortezomib)</article-title><source>Cancer Invest</source><year>2004</year><volume>22</volume><fpage>304</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">15199612</pub-id><pub-id pub-id-type="doi">10.1081/CNV-120030218</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>QM</given-names></name></person-group><article-title>The IKK NF-kappa B system: a treasure trove for drug development</article-title><source>Nat Rev Drug Discov</source><year>2004</year><volume>3</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">14708018</pub-id><pub-id pub-id-type="doi">10.1038/nrd1279</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haefner</surname><given-names>B</given-names></name></person-group><article-title>NF-kappa B: arresting a major culprit in cancer</article-title><source>Drug Discov Today</source><year>2002</year><volume>7</volume><fpage>653</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">12110242</pub-id><pub-id pub-id-type="doi">10.1016/S1359-6446(02)02309-7</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van</surname><given-names>WC</given-names></name></person-group><article-title>Nuclear factor-kappaB in development, prevention, and therapy of cancer</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>1076</fpage><lpage>1082</lpage><pub-id pub-id-type="pmid">17317814</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2221</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palombella</surname><given-names>V</given-names></name><name><surname>Rando</surname><given-names>O</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name></person-group><article-title>The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B</article-title><source>Cell</source><year>1994</year><volume>78</volume><fpage>773</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">8087845</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(94)90482-0</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>TJ</given-names></name><name><surname>Loo</surname><given-names>MA</given-names></name><name><surname>Pind</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>DB</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name><name><surname>Riordan</surname><given-names>JR</given-names></name></person-group><article-title>Multiple proteolytic systems, including the proteasome, contribute to CFTR processing</article-title><source>Cell</source><year>1995</year><volume>83</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">7553864</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(95)90241-4</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Uchiyama</surname><given-names>H</given-names></name><name><surname>Urashima</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells</article-title><source>Stem Cells</source><year>1995</year><volume>2</volume><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">8520509</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Uchiyama</surname><given-names>H</given-names></name><name><surname>Akbarali</surname><given-names>Y</given-names></name><name><surname>Urashima</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Libermann</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B</article-title><source>Blood</source><year>1996</year><volume>87</volume><fpage>1104</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">8562936</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>H</given-names></name><name><surname>Ergin</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Qin</surname><given-names>JZ</given-names></name><name><surname>Amin</surname><given-names>HM</given-names></name><name><surname>Martinez</surname><given-names>RL</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Barton</surname><given-names>K</given-names></name><name><surname>Alkan</surname><given-names>S</given-names></name></person-group><article-title>Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis</article-title><source>Br J Haematol</source><year>2001</year><volume>115</volume><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">11703322</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2141.2001.03102.x</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Dang</surname><given-names>L</given-names></name><name><surname>Castro</surname><given-names>A</given-names></name><name><surname>Palombella</surname><given-names>V</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>NF-kappa B as a therapeutic target in multiple myeloma</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>16639</fpage><lpage>16647</lpage><pub-id pub-id-type="pmid">11872748</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M200360200</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name><name><surname>Poulaki</surname><given-names>V</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Treon</surname><given-names>SP</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>4079</fpage><lpage>4086</lpage><pub-id pub-id-type="pmid">12010810</pub-id><pub-id pub-id-type="doi">10.1182/blood.V99.11.4079</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landowski</surname><given-names>TH</given-names></name><name><surname>Olashaw</surname><given-names>NE</given-names></name><name><surname>Agrawal</surname><given-names>D</given-names></name><name><surname>Dalton</surname><given-names>WS</given-names></name></person-group><article-title>Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>2417</fpage><lpage>2421</lpage><pub-id pub-id-type="pmid">12717418</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1206315</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bharti</surname><given-names>A</given-names></name><name><surname>Shishodia</surname><given-names>S</given-names></name><name><surname>Reuben</surname><given-names>J</given-names></name><name><surname>Weber</surname><given-names>D</given-names></name><name><surname>Alexanian</surname><given-names>R</given-names></name><name><surname>Raj-Vadhan</surname><given-names>S</given-names></name><name><surname>Estrov</surname><given-names>Z</given-names></name><name><surname>Talpaz</surname><given-names>M</given-names></name><name><surname>Aggarwal</surname><given-names>B</given-names></name></person-group><article-title>Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>3175</fpage><lpage>3184</lpage><pub-id pub-id-type="pmid">15070700</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-06-2151</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname><given-names>RC</given-names></name><name><surname>Bross</surname><given-names>PF</given-names></name><name><surname>Farrell</surname><given-names>AT</given-names></name><name><surname>Pazdur</surname><given-names>R</given-names></name></person-group><article-title>Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy</article-title><source>Oncologist</source><year>2003</year><volume>8</volume><fpage>508</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">14657528</pub-id><pub-id pub-id-type="doi">10.1634/theoncologist.8-6-508</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeBlanc</surname><given-names>R</given-names></name><name><surname>Catley</surname><given-names>LP</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Lentzsch</surname><given-names>S</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Goloubeva</surname><given-names>O</given-names></name><name><surname>Pien</surname><given-names>CS</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>4996</fpage><lpage>5000</lpage><pub-id pub-id-type="pmid">12208752</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsiades</surname><given-names>CS</given-names></name><name><surname>Mitsiades</surname><given-names>NS</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Treon</surname><given-names>SP</given-names></name><name><surname>Maxwell</surname><given-names>CA</given-names></name><name><surname>Pilarski</surname><given-names>L</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Hoffman</surname><given-names>RM</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>6689</fpage><lpage>6696</lpage><pub-id pub-id-type="pmid">14583463</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tassone</surname><given-names>P</given-names></name><name><surname>Neri</surname><given-names>P</given-names></name><name><surname>Carrasco</surname><given-names>D</given-names></name><name><surname>Burger</surname><given-names>R</given-names></name><name><surname>Goldmacher</surname><given-names>V</given-names></name><name><surname>Fram</surname><given-names>R</given-names></name><name><surname>Munshi</surname><given-names>V</given-names></name><name><surname>Shammas</surname><given-names>M</given-names></name><name><surname>Catley</surname><given-names>L</given-names></name><name><surname>Jacob</surname><given-names>G</given-names></name><name><surname>Venuta</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name></person-group><article-title>A clinically relevant SCID-hu in vivo model of human multiple myeloma</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>713</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">15817674</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-01-0373</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urashima</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>BP</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Pinkus</surname><given-names>GS</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Dedera</surname><given-names>DA</given-names></name><name><surname>Hoshi</surname><given-names>Y</given-names></name><name><surname>Teoh</surname><given-names>G</given-names></name><name><surname>Ogata</surname><given-names>A</given-names></name><name><surname>Treon</surname><given-names>SP</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>The development of a model for the homing of multiple myeloma cells to human bone marrow</article-title><source>Blood</source><year>1997</year><volume>90</volume><fpage>754</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">9226176</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uchiyama</surname><given-names>H</given-names></name><name><surname>Barut</surname><given-names>B</given-names></name><name><surname>Mohrbacher</surname><given-names>A</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion</article-title><source>Blood</source><year>1993</year><volume>82</volume><fpage>3712</fpage><lpage>3720</lpage><pub-id pub-id-type="pmid">8260708</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Damiano</surname><given-names>J</given-names></name><name><surname>Cress</surname><given-names>A</given-names></name><name><surname>Hazlehurst</surname><given-names>L</given-names></name><name><surname>Shtil</surname><given-names>A</given-names></name><name><surname>Dalton</surname><given-names>W</given-names></name></person-group><article-title>Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines</article-title><source>Blood</source><year>1999</year><volume>93</volume><fpage>1658</fpage><lpage>1667</lpage><pub-id pub-id-type="pmid">10029595</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neri</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Fulciniti</surname><given-names>MT</given-names></name><name><surname>Vallet</surname><given-names>S</given-names></name><name><surname>Chhetri</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Tai</surname><given-names>Y</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Tassone</surname><given-names>P</given-names></name><name><surname>Venuta</surname><given-names>S</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Raje</surname><given-names>N</given-names></name></person-group><article-title>Neutralizing B-Cell Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>5903</fpage><lpage>5909</lpage><pub-id pub-id-type="pmid">17908986</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0753</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kisselev</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name></person-group><article-title>Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates</article-title><source>Methods Enzymol</source><year>2005</year><volume>398</volume><fpage>364</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">16275343</pub-id><pub-id pub-id-type="doi">10.1016/S0076-6879(05)98030-0</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lightcap</surname><given-names>E</given-names></name><name><surname>McCormack</surname><given-names>T</given-names></name><name><surname>Pien</surname><given-names>C</given-names></name><name><surname>Chau</surname><given-names>V</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name></person-group><article-title>Proteasome inhibition measurements: clinical application</article-title><source>Clin Chem</source><year>2000</year><volume>46</volume><fpage>673</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">10794750</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berkers</surname><given-names>C</given-names></name><name><surname>Verdoes</surname><given-names>M</given-names></name><name><surname>Lichtman</surname><given-names>E</given-names></name><name><surname>Fiebiger</surname><given-names>E</given-names></name><name><surname>Kessler</surname><given-names>B</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Ploegh</surname><given-names>H</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Galardy</surname><given-names>P</given-names></name></person-group><article-title>Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib</article-title><source>Nat Methods</source><year>2005</year><volume>2</volume><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">15846363</pub-id><pub-id pub-id-type="doi">10.1038/nmeth759</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>M</given-names></name><name><surname>Ruckrich</surname><given-names>T</given-names></name><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Gogel</surname><given-names>J</given-names></name><name><surname>Beck</surname><given-names>A</given-names></name><name><surname>Kammer</surname><given-names>W</given-names></name><name><surname>Berkers</surname><given-names>C</given-names></name><name><surname>Burg</surname><given-names>D</given-names></name><name><surname>Overkleeft</surname><given-names>H</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Driessen</surname><given-names>C</given-names></name></person-group><article-title>Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17024115</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404414</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orlowski</surname><given-names>R</given-names></name><name><surname>Stinchcombe</surname><given-names>T</given-names></name><name><surname>Mitchell</surname><given-names>B</given-names></name><name><surname>Shea</surname><given-names>T</given-names></name><name><surname>Baldwin</surname><given-names>A</given-names></name><name><surname>Stahl</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Esseltine</surname><given-names>D</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name><name><surname>Pien</surname><given-names>C</given-names></name><name><surname>Guerciolini</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Depcik-Smith</surname><given-names>N</given-names></name><name><surname>Bhagat</surname><given-names>R</given-names></name><name><surname>Lehman</surname><given-names>M</given-names></name><name><surname>Novick</surname><given-names>S</given-names></name><name><surname>O'Connor</surname><given-names>O</given-names></name><name><surname>Soignet</surname><given-names>S</given-names></name></person-group><article-title>Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>4420</fpage><lpage>4427</lpage><pub-id pub-id-type="pmid">12431963</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2002.01.133</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Berenson</surname><given-names>J</given-names></name><name><surname>Singhal</surname><given-names>S</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Irwin</surname><given-names>D</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Srkalovic</surname><given-names>G</given-names></name><name><surname>Alsina</surname><given-names>M</given-names></name><name><surname>Alexanian</surname><given-names>R</given-names></name><name><surname>Siegel</surname><given-names>D</given-names></name><name><surname>Orlowski</surname><given-names>RZ</given-names></name><name><surname>Kuter</surname><given-names>D</given-names></name><name><surname>Limentani</surname><given-names>SA</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Esseltine</surname><given-names>DL</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Schenkein</surname><given-names>DP</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>A phase 2 study of bortezomib in relapsed, refractory myeloma</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>2609</fpage><lpage>2617</lpage><pub-id pub-id-type="pmid">12826635</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa030288</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Schuster</surname><given-names>MW</given-names></name><name><surname>Irwin</surname><given-names>D</given-names></name><name><surname>Stadtmauer</surname><given-names>EA</given-names></name><name><surname>Facon</surname><given-names>T</given-names></name><name><surname>Harousseau</surname><given-names>JL</given-names></name><name><surname>Ben-Yehuda</surname><given-names>D</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name><name><surname>Reece</surname><given-names>D</given-names></name><name><surname>San-Miguel</surname><given-names>JF</given-names></name><name><surname>Blade</surname><given-names>J</given-names></name><name><surname>Boccadoro</surname><given-names>M</given-names></name><name><surname>Cavenagh</surname><given-names>J</given-names></name><name><surname>Dalton</surname><given-names>WS</given-names></name><name><surname>Boral</surname><given-names>AL</given-names></name><name><surname>Esseltine</surname><given-names>DL</given-names></name><name><surname>Porter</surname><given-names>JB</given-names></name><name><surname>Schenkein</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Bortezomib or high-dose dexamethasone for relapsed multiple myeloma</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>2487</fpage><lpage>2498</lpage><pub-id pub-id-type="pmid">15958804</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa043445</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Berenson</surname><given-names>J</given-names></name><name><surname>Singhal</surname><given-names>S</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Irwin</surname><given-names>D</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Esseltine</surname><given-names>D</given-names></name><name><surname>Schenkein</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>2977</fpage><lpage>2981</lpage><pub-id pub-id-type="pmid">16020506</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-02-0691</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Schuster</surname><given-names>M</given-names></name><name><surname>Irwin</surname><given-names>D</given-names></name><name><surname>Stadtmauer</surname><given-names>E</given-names></name><name><surname>Facon</surname><given-names>T</given-names></name><name><surname>Harousseau</surname><given-names>J</given-names></name><name><surname>Ben-Yehuda</surname><given-names>D</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name><name><surname>Reece</surname><given-names>D</given-names></name><name><surname>San</surname><given-names>MJ</given-names></name><name><surname>Blade</surname><given-names>J</given-names></name><name><surname>Boccadoro</surname><given-names>M</given-names></name><name><surname>Cavenagh</surname><given-names>J</given-names></name><name><surname>Alsina</surname><given-names>M</given-names></name><name><surname>Rajkumar</surname><given-names>S</given-names></name><name><surname>Lacy</surname><given-names>M</given-names></name><name><surname>Jakubowiak</surname><given-names>A</given-names></name><name><surname>Dalton</surname><given-names>W</given-names></name><name><surname>Boral</surname><given-names>A</given-names></name><name><surname>Esseltine</surname><given-names>D</given-names></name><name><surname>Schenkein</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>3557</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">17690257</pub-id><pub-id pub-id-type="doi">10.1182/blood-2006-08-036947</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Waller</surname><given-names>EK</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Orlowski</surname><given-names>RZ</given-names></name><name><surname>Giver</surname><given-names>CR</given-names></name><name><surname>Jaye</surname><given-names>DL</given-names></name><name><surname>Francis</surname><given-names>D</given-names></name><name><surname>Giusti</surname><given-names>S</given-names></name><name><surname>Torre</surname><given-names>C</given-names></name><name><surname>Barlogie</surname><given-names>B</given-names></name><name><surname>Berenson</surname><given-names>JR</given-names></name><name><surname>Singhal</surname><given-names>S</given-names></name><name><surname>Schenkein</surname><given-names>DP</given-names></name><name><surname>Esseltine</surname><given-names>DL</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Heffner</surname><given-names>LT</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>3777</fpage><lpage>3784</lpage><pub-id pub-id-type="pmid">16099887</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-03-1173</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname><given-names>OA</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Moskowitz</surname><given-names>C</given-names></name><name><surname>Muzzy</surname><given-names>J</given-names></name><name><surname>MacGregor-Cortelli</surname><given-names>B</given-names></name><name><surname>Stubblefield</surname><given-names>M</given-names></name><name><surname>Straus</surname><given-names>D</given-names></name><name><surname>Portlock</surname><given-names>C</given-names></name><name><surname>Hamlin</surname><given-names>P</given-names></name><name><surname>Choi</surname><given-names>E</given-names></name><name><surname>Dumetrescu</surname><given-names>O</given-names></name><name><surname>Esseltine</surname><given-names>D</given-names></name><name><surname>Trehu</surname><given-names>E</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Schenkein</surname><given-names>D</given-names></name><name><surname>Zelenetz</surname><given-names>AD</given-names></name></person-group><article-title>Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>676</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">15613699</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.02.050</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name><name><surname>Poulaki</surname><given-names>V</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Fanourakis</surname><given-names>G</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Bailey</surname><given-names>C</given-names></name><name><surname>Joseph</surname><given-names>M</given-names></name><name><surname>Libermann</surname><given-names>TA</given-names></name><name><surname>Treon</surname><given-names>SP</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Molecular sequelae of proteasome inhibition in human multiple myeloma cells</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>14374</fpage><lpage>14379</lpage><pub-id pub-id-type="pmid">12391322</pub-id><pub-id pub-id-type="doi">10.1073/pnas.202445099</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Shringarpure</surname><given-names>R</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Ohtake</surname><given-names>Y</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>6174</fpage><lpage>6177</lpage><pub-id pub-id-type="pmid">14559800</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Kharbanda</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>17593</fpage><lpage>17596</lpage><pub-id pub-id-type="pmid">12665525</pub-id><pub-id pub-id-type="doi">10.1074/jbc.C300076200</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Schlossman</surname><given-names>R</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341</article-title><source>Blood</source><year>2003</year><volume>101</volume><fpage>1530</fpage><lpage>1534</lpage><pub-id pub-id-type="pmid">12393500</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-08-2543</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Sattler</surname><given-names>M</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>6296</fpage><lpage>6300</lpage><pub-id pub-id-type="pmid">13679868</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1206734</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Poulaki</surname><given-names>V</given-names></name><name><surname>Tai</surname><given-names>YT</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Fanourakis</surname><given-names>G</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Bailey</surname><given-names>C</given-names></name><name><surname>Joseph</surname><given-names>M</given-names></name><name><surname>Libermann</surname><given-names>TA</given-names></name><name><surname>Schlossman</surname><given-names>R</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications</article-title><source>Blood</source><year>2003</year><volume>101</volume><fpage>2377</fpage><lpage>2380</lpage><pub-id pub-id-type="pmid">12424198</pub-id><pub-id pub-id-type="doi">10.1182/blood-2002-06-1768</pub-id></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Tonon</surname><given-names>G</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>585</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">17646864</pub-id><pub-id pub-id-type="doi">10.1038/nrc2189</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Obeng</surname><given-names>E</given-names></name><name><surname>Carlson</surname><given-names>L</given-names></name><name><surname>Gutman</surname><given-names>D</given-names></name><name><surname>Harrington</surname><given-names>W</given-names><suffix>Jr</suffix></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Boise</surname><given-names>L</given-names></name></person-group><article-title>Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>4907</fpage><lpage>4916</lpage><pub-id pub-id-type="pmid">16507771</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-08-3531</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nawrocki</surname><given-names>ST</given-names></name><name><surname>Carew</surname><given-names>JS</given-names></name><name><surname>Dunner</surname><given-names>K</given-names><suffix>Jr</suffix></name><name><surname>Boise</surname><given-names>LH</given-names></name><name><surname>Chiao</surname><given-names>PJ</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>McConkey</surname><given-names>DJ</given-names></name></person-group><article-title>Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>11510</fpage><lpage>11519</lpage><pub-id pub-id-type="pmid">16357160</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2394</pub-id></citation></ref><ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Proteasome inhibition in multiple myeloma: therapeutic implication</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2005</year><volume>45</volume><fpage>465</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">15822185</pub-id><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.100037</pub-id></citation></ref><ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joazeiro</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name></person-group><article-title>Proteasome inhibitor drugs on the rise</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>7840</fpage><lpage>7842</lpage><pub-id pub-id-type="pmid">16861477</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2033</pub-id></citation></ref><ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>McMullan</surname><given-names>C</given-names></name><name><surname>Poulaki</surname><given-names>V</given-names></name><name><surname>Kung</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>F</given-names></name><name><surname>Morgan</surname><given-names>G</given-names></name><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Shringarpure</surname><given-names>R</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Bailey</surname><given-names>C</given-names></name><name><surname>Joseph</surname><given-names>M</given-names></name><name><surname>Libermann</surname><given-names>T</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Antimyeloma activity of heat shock protein-90 inhibition</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>1092</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">16234364</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-03-1158</pub-id></citation></ref><ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chanan-Khan</surname><given-names>A</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Alsina</surname><given-names>M</given-names></name><name><surname>Carroll</surname><given-names>M</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Krishnan</surname><given-names>A</given-names></name><name><surname>Albitar</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Cropp</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Phase 1 Clinical Trial of KOS-953 + Bortezomib (BZ) in Relapsed Refractory Multiple Myeloma (MM) [abstract]</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>362</fpage><pub-id pub-id-type="pmid">15774616</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-02-0669</pub-id></citation></ref><ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Ishitsuka</surname><given-names>K</given-names></name><name><surname>Yasui</surname><given-names>H</given-names></name><name><surname>Raje</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Hideshima</surname><given-names>H</given-names></name><name><surname>Bonham</surname><given-names>L</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Singer</surname><given-names>JW</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>3121</fpage><lpage>3129</lpage><pub-id pub-id-type="pmid">15735676</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208522</pub-id></citation></ref><ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Ishitsuka</surname><given-names>K</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Tai</surname><given-names>YT</given-names></name><name><surname>Hamasaki</surname><given-names>M</given-names></name><name><surname>Raje</surname><given-names>N</given-names></name><name><surname>Hideshima</surname><given-names>H</given-names></name><name><surname>Schreiner</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>AN</given-names></name><name><surname>Navas</surname><given-names>T</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Higgins</surname><given-names>LS</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>8766</fpage><lpage>8776</lpage><pub-id pub-id-type="pmid">15480425</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208118</pub-id></citation></ref><ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navas</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Reddy</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Haghnazari</surname><given-names>E</given-names></name><name><surname>Henson</surname><given-names>M</given-names></name><name><surname>Stebbins</surname><given-names>E</given-names></name><name><surname>Kerr</surname><given-names>I</given-names></name><name><surname>O'Young</surname><given-names>G</given-names></name><name><surname>Kapoun</surname><given-names>A</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Mavunkel</surname><given-names>B</given-names></name><name><surname>Perumattam</surname><given-names>J</given-names></name><name><surname>Luedtke</surname><given-names>G</given-names></name><name><surname>Dugar</surname><given-names>S</given-names></name><name><surname>Medicherla</surname><given-names>S</given-names></name><name><surname>Protter</surname><given-names>A</given-names></name><name><surname>Schreiner</surname><given-names>G</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Higgins</surname><given-names>L</given-names></name></person-group><article-title>Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo</article-title><source>Leukemia</source><year>2006</year><volume>20</volume><fpage>1017</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">16617327</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404200</pub-id></citation></ref><ref id="B89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Shima</surname><given-names>Y</given-names></name><name><surname>Raje</surname><given-names>N</given-names></name><name><surname>Davies</surname><given-names>FE</given-names></name><name><surname>Tai</surname><given-names>YT</given-names></name><name><surname>Treon</surname><given-names>SP</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Schlossman</surname><given-names>RL</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Muller</surname><given-names>G</given-names></name><name><surname>Stirling</surname><given-names>DI</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>2943</fpage><lpage>2950</lpage><pub-id pub-id-type="pmid">11049970</pub-id></citation></ref><ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Podar</surname><given-names>K</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Shringarpure</surname><given-names>R</given-names></name><name><surname>Catley</surname><given-names>L</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Tai</surname><given-names>YT</given-names></name><name><surname>Suh</surname><given-names>N</given-names></name><name><surname>Gribble</surname><given-names>GW</given-names></name><name><surname>Honda</surname><given-names>T</given-names></name><name><surname>Schlossman</surname><given-names>R</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Sporn</surname><given-names>MB</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>3158</fpage><lpage>3166</lpage><pub-id pub-id-type="pmid">15070698</pub-id><pub-id pub-id-type="doi">10.1182/blood-2003-08-2873</pub-id></citation></ref><ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barlogie</surname><given-names>B</given-names></name></person-group><article-title>Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience</article-title><source>Semin Hematol</source><year>2003</year><volume>40</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">15015894</pub-id><pub-id pub-id-type="doi">10.1053/j.seminhematol.2003.09.005</pub-id></citation></ref><ref id="B92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orlowski</surname><given-names>RZ</given-names></name><name><surname>Voorhees</surname><given-names>PM</given-names></name><name><surname>Garcia</surname><given-names>RA</given-names></name><name><surname>Hall</surname><given-names>MD</given-names></name><name><surname>Kudrik</surname><given-names>FJ</given-names></name><name><surname>Allred</surname><given-names>T</given-names></name><name><surname>Johri</surname><given-names>AR</given-names></name><name><surname>Jones</surname><given-names>PE</given-names></name><name><surname>Ivanova</surname><given-names>A</given-names></name><name><surname>Van Deventer</surname><given-names>HW</given-names></name><name><surname>Gabriel</surname><given-names>DA</given-names></name><name><surname>Shea</surname><given-names>TC</given-names></name><name><surname>Mitchell</surname><given-names>BS</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Esseltine</surname><given-names>DL</given-names></name><name><surname>Trehu</surname><given-names>EG</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Lehman</surname><given-names>MJ</given-names></name><name><surname>Natoli</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>JM</given-names></name><name><surname>Lindley</surname><given-names>CM</given-names></name><name><surname>Dees</surname><given-names>EC</given-names></name></person-group><article-title>Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>3058</fpage><lpage>3065</lpage><pub-id pub-id-type="pmid">15626743</pub-id><pub-id pub-id-type="doi">10.1182/blood-2004-07-2911</pub-id></citation></ref><ref id="B93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orlowski</surname><given-names>RZ</given-names></name><name><surname>Nagler</surname><given-names>A</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Blade</surname><given-names>J</given-names></name><name><surname>Hajek</surname><given-names>R</given-names></name><name><surname>Spencer</surname><given-names>A</given-names></name><name><surname>San Miguel</surname><given-names>J</given-names></name><name><surname>Robak</surname><given-names>T</given-names></name><name><surname>Dmoszynska</surname><given-names>A</given-names></name><name><surname>Horvath</surname><given-names>N</given-names></name><name><surname>Spicka</surname><given-names>I</given-names></name><name><surname>Sutherland</surname><given-names>HJ</given-names></name><name><surname>Suvorov</surname><given-names>AN</given-names></name><name><surname>Zhuang</surname><given-names>SH</given-names></name><name><surname>Parekh</surname><given-names>T</given-names></name><name><surname>Xiu</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Rackoff</surname><given-names>W</given-names></name><name><surname>Harousseau</surname><given-names>JL</given-names></name></person-group><article-title>Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>3892</fpage><lpage>3901</lpage><pub-id pub-id-type="pmid">17679727</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2006.10.5460</pub-id></citation></ref><ref id="B94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kopito</surname><given-names>RR</given-names></name></person-group><article-title>Aggresomes, inclusion bodies and protein aggregation</article-title><source>Trends Cell Biol</source><year>2000</year><volume>10</volume><fpage>524</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">11121744</pub-id><pub-id pub-id-type="doi">10.1016/S0962-8924(00)01852-3</pub-id></citation></ref><ref id="B95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>8567</fpage><lpage>8572</lpage><pub-id pub-id-type="pmid">15937109</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0503221102</pub-id></citation></ref><ref id="B96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nawrocki</surname><given-names>ST</given-names></name><name><surname>Carew</surname><given-names>JS</given-names></name><name><surname>Pino</surname><given-names>MS</given-names></name><name><surname>Highshaw</surname><given-names>RA</given-names></name><name><surname>Andtbacka</surname><given-names>RH</given-names></name><name><surname>Dunner</surname><given-names>K</given-names><suffix>Jr</suffix></name><name><surname>Pal</surname><given-names>A</given-names></name><name><surname>Bornmann</surname><given-names>WG</given-names></name><name><surname>Chiao</surname><given-names>PJ</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Xiong</surname><given-names>H</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>McConkey</surname><given-names>DJ</given-names></name></person-group><article-title>Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>3773</fpage><lpage>3781</lpage><pub-id pub-id-type="pmid">16585204</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2961</pub-id></citation></ref><ref id="B97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Catley</surname><given-names>L</given-names></name><name><surname>Weisberg</surname><given-names>E</given-names></name><name><surname>Kiziltepe</surname><given-names>T</given-names></name><name><surname>Tai</surname><given-names>Y</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Neri</surname><given-names>P</given-names></name><name><surname>Tassone</surname><given-names>P</given-names></name><name><surname>Atadja</surname><given-names>P</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>3441</fpage><lpage>3449</lpage><pub-id pub-id-type="pmid">16728695</pub-id><pub-id pub-id-type="doi">10.1182/blood-2006-04-016055</pub-id></citation></ref><ref id="B98"><citation citation-type="other"><article-title>Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma</article-title><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00532389?term=NCT00532389&#x00026;rank=1"/></citation></ref><ref id="B99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feling</surname><given-names>RH</given-names></name><name><surname>Buchanan</surname><given-names>GO</given-names></name><name><surname>Mincer</surname><given-names>TJ</given-names></name><name><surname>Kauffman</surname><given-names>CA</given-names></name><name><surname>Jensen</surname><given-names>PR</given-names></name><name><surname>Fenical</surname><given-names>W</given-names></name></person-group><article-title>Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora</article-title><source>Angew Chem Int Ed Engl</source><year>2003</year><volume>42</volume><fpage>355</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">12548698</pub-id><pub-id pub-id-type="doi">10.1002/anie.200390115</pub-id></citation></ref><ref id="B100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macherla</surname><given-names>V</given-names></name><name><surname>Mitchell</surname><given-names>S</given-names></name><name><surname>Manam</surname><given-names>R</given-names></name><name><surname>Reed</surname><given-names>K</given-names></name><name><surname>Chao</surname><given-names>T</given-names></name><name><surname>Nicholson</surname><given-names>B</given-names></name><name><surname>Deyanat-Yazdi</surname><given-names>G</given-names></name><name><surname>Mai</surname><given-names>B</given-names></name><name><surname>Jensen</surname><given-names>P</given-names></name><name><surname>Fenical</surname><given-names>W</given-names></name><name><surname>Neuteboom</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>K</given-names></name><name><surname>Palladino</surname><given-names>M</given-names></name><name><surname>Potts</surname><given-names>B</given-names></name></person-group><article-title>Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor</article-title><source>J Med Chem</source><year>2005</year><volume>48</volume><fpage>3684</fpage><lpage>3687</lpage><pub-id pub-id-type="pmid">15916417</pub-id><pub-id pub-id-type="doi">10.1021/jm048995+</pub-id></citation></ref><ref id="B101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groll</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>R</given-names></name><name><surname>Potts</surname><given-names>BC</given-names></name></person-group><article-title>Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding</article-title><source>J Am Chem Soc</source><year>2006</year><volume>128</volume><fpage>5136</fpage><lpage>5141</lpage><pub-id pub-id-type="pmid">16608349</pub-id><pub-id pub-id-type="doi">10.1021/ja058320b</pub-id></citation></ref><ref id="B102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>S</given-names></name><name><surname>Krupnik</surname><given-names>Y</given-names></name><name><surname>Keating</surname><given-names>M</given-names></name><name><surname>Chandra</surname><given-names>J</given-names></name><name><surname>Palladino</surname><given-names>M</given-names></name><name><surname>McConkey</surname><given-names>D</given-names></name></person-group><article-title>The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia</article-title><source>Mol Cancer Ther</source><year>2006</year><volume>5</volume><fpage>1836</fpage><lpage>1843</lpage><pub-id pub-id-type="pmid">16891470</pub-id><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0066</pub-id></citation></ref><ref id="B103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oberdorf</surname><given-names>J</given-names></name><name><surname>Carlson</surname><given-names>EJ</given-names></name><name><surname>Skach</surname><given-names>WR</given-names></name></person-group><article-title>Redundancy of mammalian proteasome beta subunit function during endoplasmic reticulum associated degradation</article-title><source>Biochemistry</source><year>2001</year><volume>40</volume><fpage>13397</fpage><lpage>13405</lpage><pub-id pub-id-type="pmid">11683650</pub-id><pub-id pub-id-type="doi">10.1021/bi011322y</pub-id></citation></ref><ref id="B104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demo</surname><given-names>SD</given-names></name><name><surname>Kirk</surname><given-names>CJ</given-names></name><name><surname>Aujay</surname><given-names>MA</given-names></name><name><surname>Buchholz</surname><given-names>TJ</given-names></name><name><surname>Dajee</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>MN</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Laidig</surname><given-names>GJ</given-names></name><name><surname>Lewis</surname><given-names>ER</given-names></name><name><surname>Parlati</surname><given-names>F</given-names></name><name><surname>Shenk</surname><given-names>KD</given-names></name><name><surname>Smyth</surname><given-names>MS</given-names></name><name><surname>Sun</surname><given-names>CM</given-names></name><name><surname>Vallone</surname><given-names>MK</given-names></name><name><surname>Woo</surname><given-names>TM</given-names></name><name><surname>Molineaux</surname><given-names>CJ</given-names></name><name><surname>Bennett</surname><given-names>MK</given-names></name></person-group><article-title>Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>6383</fpage><lpage>6391</lpage><pub-id pub-id-type="pmid">17616698</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4086</pub-id></citation></ref><ref id="B105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stapnes</surname><given-names>C</given-names></name><name><surname>Doskeland</surname><given-names>AP</given-names></name><name><surname>Hatfield</surname><given-names>K</given-names></name><name><surname>Ersvaer</surname><given-names>E</given-names></name><name><surname>Ryningen</surname><given-names>A</given-names></name><name><surname>Lorens</surname><given-names>JB</given-names></name><name><surname>Gjertsen</surname><given-names>BT</given-names></name><name><surname>Bruserud</surname><given-names>O</given-names></name></person-group><article-title>The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells</article-title><source>Br J Haematol</source><year>2007</year><volume>136</volume><fpage>814</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">17341267</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2141.2007.06504.x</pub-id></citation></ref><ref id="B106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Voorhees</surname><given-names>PM</given-names></name><name><surname>Strader</surname><given-names>JS</given-names></name><name><surname>Shenk</surname><given-names>KD</given-names></name><name><surname>Sun</surname><given-names>CM</given-names></name><name><surname>Demo</surname><given-names>SD</given-names></name><name><surname>Bennett</surname><given-names>MK</given-names></name><name><surname>van Leeuwen</surname><given-names>FW</given-names></name><name><surname>Chanan-Khan</surname><given-names>AA</given-names></name><name><surname>Orlowski</surname><given-names>RZ</given-names></name></person-group><article-title>Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>3281</fpage><lpage>3290</lpage><pub-id pub-id-type="pmid">17591945</pub-id><pub-id pub-id-type="doi">10.1182/blood-2007-01-065888</pub-id></citation></ref><ref id="B107"><citation citation-type="other"><article-title>Safety Study of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies</article-title><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00150462?term=NCT00150462&#x00026;rank=1"/></citation></ref><ref id="B108"><citation citation-type="other"><article-title>Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma</article-title><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00511238?term=NCT00511238&#x00026;rank=1"/></citation></ref><ref id="B109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Proteasome inhibitor therapy in multiple myeloma</article-title><source>Mol Cancer Ther</source><year>2005</year><volume>4</volume><fpage>686</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">15827343</pub-id><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-04-0338</pub-id></citation></ref><ref id="B110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cusack</surname><given-names>JC</given-names><suffix>Jr</suffix></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Chao</surname><given-names>TH</given-names></name><name><surname>Pien</surname><given-names>C</given-names></name><name><surname>Niu</surname><given-names>W</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>Neuteboom</surname><given-names>ST</given-names></name><name><surname>Palladino</surname><given-names>MA</given-names></name></person-group><article-title>NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>6758</fpage><lpage>6764</lpage><pub-id pub-id-type="pmid">17121896</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1151</pub-id></citation></ref></ref-list></back></article>


